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PHARMAC. BIOCHEM. BEHAV. 16(6) %%972, 1982.--We have proposed that chronic stress may produce motiva- 
tional, behavioral, and neuroendocrine symptoms in rats resembling endogenous depression in humans. The chronic stress 
model has proved responsive to chronic treatment by antidepressant drugs. Two issues concerning this effect remain 
unresolved, these being; the requirement of drug chronicity, and treatment outcome to different drug doses. The present 
experiment examined both issues in a factorial design in which vehicle and two doses of the tricyclic antidepressant 
imipramine were varied across 2 treatment periods; acute (1 hr) and chronic (3 weeks). Both factors were found to 
significantly interact with treatment outcome, suggesting that chronic treatment is necessary for recovery and that this 
outcome is dependent upon drug level. 
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IN a recent series of papers (e.g., ]2,3]), we have suggested 
that chronic stress may produce a behavioral, motivational, 
and neuroendocrine syndrome in the rat resembling 
endogenous depression in humans. The syndrome has been 
demonstrated to respond exclusively to clinically relevant 
therapeutic treatments. However, two objections might be 
raised to previous demonstrations. First, the necessity for 
chronic drug treatment might be questioned; it is possible, 
for example, that acute drug administration, a treatment with 
no or even adverse clinical effects [4], would be as effective 
as chronic treatment. Such an outcome would raise ques- 
tions concerning the validity of the model. Second, it might 
be questioned whether treatment outcome depends upon 
drug dosage level. Since subclinical doses of antidepressants 
are not normally effective [6] such an outcome again would 
call the validity of the stress model into question. In the 
present design both level and chronicity of drug treatment 
were parametrically varied to allow an assessment of both 
factors and their interactions. 
METHOD 
Subjects 
Adult male Sprague-Dawley rats (n= 144; 6/cell, Charles 
River Farms) were double housed in standard 25 × 18 × 17 cm 
rack mounted cages with food (Teklad 4.0%, fat rodent diet 
S-0836) and tap water continuously available and 12 hr/12 hr 
lighting (lights on=0700--1900 hr). 
Apparatus and Behavioral Procedure 
Testing was carried out in a 1.22 m2×45 cm height white 
Piexiglas open field. Each subject was placed in the field for 
a single 6 minute observation period, with the field cleaned 
thoroughly between tests. A four-factorial (2×2×2×3)  ex- 
perimental design was employed with the factors being: (!) 
acute stress vs control (hereafter the acute factor); rats were 
either removed from housing and tested immediately (<20 
sec) or removed and stressed with a 1 hour exposure to 95 dB 
of white noise prior to the open field test (see [2,3] for further 
procedural details); (2) chronic stress vs control (hereafter 
the chronic factor), rats were either exposed to 3 weeks of 
chronic intermittent stress, with stressors including: expo- 
sure to sixty minutes of unpredictable shock (average I mA, 
1-10 sec duration; average i shock/minute (3 exposures); 40 
hours' food deprivation (2 times); cold swim at 4.0°C for 5 
minutes (3 exposures); 40 hours' water deprivation (2 times); 
5 minutes" exposure to heat stress at 40°C (2 times); 30 min- 
utes' shaker stress (2 times); reversal of day/night cycle (2 
times; stressors were delivered in a semirandom fashion 
every 2-3 days throughout the day/night cycle from 0:800 
through 22:00 hr; order of stress presentation has been pre- 
sented elsewhere see [2,3]; control rats for chronic stress 
were left undisturbed except for normal cage maintenance 
(changing of food, water, and bedding) for the 3 week 
period.); (3) acute vs chronic drug treatment (drug chronicity 
factor), rats were administered vehicle or drug either 1 hour 
prior to testing (acute) or on a once daily basis for the 3 week 
~Send reprint requests to R. J. Katz, Department of Psychology, The Johns Hopkins University, 34th and Charles Streets, Baltimore, MD 
21218. 
Copyr igh t  ,e 1982 A N K H O  In t e rna t iona l  Inc.--0091-3057/82/060969-04503.00/0 










0 25 5.0 
ContrOl 
Unstressed 






0 25 50 
Control 
Unstressed 
0 25 50 0 25 50 0 25 50 mg/kg 25 50 
Acutely Chronically Expenmental Acutely 
Stressed On ly  Stressed Only Stressed Oniy 
0 25 50 0 25 50 mg/kg 
ChronJCal[y Expenmentol 
Stressed Only 
FIG. 1. Effects of acute and chronic stress and drug administration upon open field motor activity in the rat (mean outside squares/3 
rain_ standard error). A single placement is used and a factorial experimental design is employed. Right-hand side of figure displays acute (I hr) 
drug administration effects and left-hand side of figure displays chronic (3 week) drug administration effects. 
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FIG. 2. Effects o f  acute and chronic stress and drug administration upon open field defecation in the rat (mean bolus count/per ses- 
s ion_ standard error). A single placement is used and a factorial experimental design is employed. Right-hand side of figure displays acute ( 1 
hr) drug administration effects and left-hand side of figure displays chronic (3 week) drug administration effects. 
period corresponding to the chronic stress period; and (4) 
drug dose, rats were exposed to vehicle (0.9% sodium 
chloride) or 2.5 or 5.0 mg/kg of imipramine HCI, 1 ml/kg 
intraperitoneally. All drugs were prepared within 72 hr of 
use. 
Four behavioral measures were examined. All measures 
have been described in detail in previous reports [2,3]. Initial 
motor activity in the periphery of the field (min 0-3) was 
designated outside square activity. A bolus count at the close 
of testing was designated defecation score. Latencies (in sec) 
to leave initial home square, and for defecation were also 
collected and analyzed. 
Statistical Analysis 
All data are presented as means and standard errors. 
Analysis was by 4-factor analysis of variance based upon the 
above factors. In the interests of brevity interaction effects 
are reported only if they reach a level of statistical signifi- 
cance of p<0.05. 
R E S U L T S  
Overall, the behaviorally activating effects of acute stress 
were demonstrated, as was their reduction by chronic stress 
and reinstatement by chronic drug treatment. Acute drug 
treatment proved ineffective. Drug dose also affected 
outcome. Findings were confirmed statistically based upon 
main and interaction effects as reported below. Results are 
presented graphically in Figs. 1-4. 
The above pattern of results may be seen for the initial 
activity scores which are presented in Fig. i. Activity was 
significantly increased following acute stress, and this was 
blunted by a history of prior stress. Chronic, but not acute, 
drug treatment restored the activating effects of acute stress. 
Main effects for drug chronicity, acute stress, and chronic 
stress were significant, F's(1,15)=18.1, 15.8, 118.6 in all 
cases, p<0.001; however, a main effect of drug dose was 
not, F(2,15)= 1.8, n.s. In further support of the hypothesized 
interactions chronic stress affected responding to acute 
stress, F(I,15)=42.2, p<0.001, and this in turn interacted 
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FIG. 3. Effects of acute and chronic stress and drug administration upon open field activity in the rat. Mean latency scores-z-S.E.M. (in sec) 
are presented, and a factorial experimental design is employed. Right-hand side of figure displays acute ( 1 hr) drug administration effects and 
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FIG. 4. Effects of acute and chronic stress and drug administration upon open field defecation (mean latency +S.E.M. (sec)). A single 
placement is used and a factorial experimental design is employed. Right-hand side of figure displays acute ( 1 hr) drug administration effects 
and left-hand side of figure displays chronic (3 week) drug administration effects. 
with drug dosage, F(2,15)= 12.3,p<0.0001. Other significant 
interactions included acute stress by drug dose, F(2,15) = 3.9, 
p<0.05,  and the three way interactions of drug chronicity 
and dose with acute stress, F(2,15)=4.6, p<0.05,  and 
chronic stress, F(2,15)=4.0, p<0.05.  
Effects of treatments and their combinations upon the 
defecation measure are presented in Fig. 2. Main effects for 
drug chronicity, acute stress, chronic stress, and drug dos- 
age level were significant, Fs=4.6,  6.9, 149.9, 14.4, dfs as 
above, all p ' s<0.05) .  An interaction of acute and chronic 
stress again was present,  F(1,15)=7.4, p<0.001,  as was the 
interaction of acute and chronic stress with drug dose, 
F(2,15)=8.0, while other interaction effects were not signifi- 
cant. 
Effects upon motor latencies are presented in the third 
figure. Main effects for drug chronicity and chronic stress 
were significant, F=3.8 ,  26.3, df as above, p<0.05,  while 
main effects for acute stress and drug dosage were not, 
F ' s=0 .3 ,  1.3, df as above, p>0.05.  A significant interaction 
of acute and chronic stress was found, F(1,15)=i3.7, 
p<0.001,  and this was dependent upon chronic drug adminis- 
tration, F=6.4 ,  p<0.05.  Other effects include drug chron- 
icity with acute stress, F(1,15=4.5, p<0.05,  and drug dose 
with acute stress, F(2,05)=4. i,  p<0.05,  and the 3 way inter- 
action of  drug chronicity, stress chronicity and drug dose, 
F(2,15) =4.7, p<0.05.  
Effects upon defecation latencies are presented in the 
final figure (Fig. 4). Main effects of acute stress and chronic 
stress were present, F ' s=57.8 ,  137.4, df as above, 
p<0.00001, while main effects for drug chronicity and level 
were not, F ' s=0 .5 ,  0.3. An interaction of acute and chronic 
stress was present, F=55.5,  as were significant influences of 
drug dosage and chronicity upon the above, F=4.1,  5.0. 
D I S C U S S I O N  
The above analysis routinely confirmed the influences of  
chronic drug administration and chronic stress upon the de- 
pression model, as well as the normal interaction of acute 
and chronic stress, and higher order interactions of both 
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stress factors with chronic drug treatment. Acute stress was 
a significant factor in most analyses, with drug dosage by 
itself generally playing a lesser role. Indeed, dosage per se 
did not significantly affect behavior in most cases. This 
might be expected on purely statistical grounds given the 
predominance of control groups which were not affected by 
drug treatment. However, dose did interact with chronic 
stress, or with the combined effects of chronic and acute 
stress, as might be predicted. Of the 4 measures, in only one 
case (defecation latency, see Fig. 3) and in that case to a 
rather limited degree, was an acute antidepressant effect ob- 
served. Careful examination of this finding points to several 
possible explanations. It might be noted, for example, that 
the unstressed latency baseline was increasing at this point, 
thus, the change may not be stress-specific. In addition, 
chronic treatment is significantly superior to acute treat- 
ment. The overall success of chronic drug effects upon all 
measures must again be emphasized. The present findings 
demonstrate that treatment regimens effective in the stress 
model may resemble clinical treatments upon such critical 
variables as time course and dose. This in turn. suggests the 
chronic stress model bears several similarities to depression. 
In the present report four measures were taken. If an 
analogy is to be drawn with clinical findings then it should be 
kept in mind that monotonic dose-response relationships are 
more difficult to demonstrate in clinical research settings 
than are nominal relationships between treatment and im- 
provement beyond some criterion. Thus it might be argued 
that at a level of face validity a binary measure evaluated 
non-parametrically, or some measure sensitive to a non- 
monotonic course of improvement, is most appropriate. Of 
the major behavioral measures the activity measure most 
directly demonstrates a "therapeutic window'" involving 
non-monotonic improvement. Thus of the broadly defined 
categories of activity and defecation the former may be more 
representative of a clinical picture. It should be noted that 
for the rat these measures often vary inversely under normal 
circumstances of first exposure. The nonlinear trend in ac- 
tivity is therefore of particular interest. 
The present interpretation presupposes that imip- 
ramine given chronically is not itself debilitating. One side 
effect of chronic imipramine, for example, is a relative re- 
duction in normal weight gain. Factors such as anorexia, 
illness, and debilitation are best controlled for by the use of 
active control substances (i.e., nonantidepressants with simi- 
lar profiles of side effects). In this regard it might be noted 
that scopolamine, a potent anticholinergic; amphetamine, a 
catecholamine releaser: and other psychotropic compounds, 
e.g., tripellinamine, oxazepam, and haloperidol have been 
evaluated in the stress model. Related doses and identical 
time courses have been employed, and in no case has a simi- 
lar behavioral profile been observed. On the other hand 
chronic electroconvulsive shock and monoamine oxidase 
inhibitors, which are clinically effective, but quite different 
in their side effects in comparison with imipramine appear 
similar to the latter in their effects upon stress and open field 
behavior. Thus, there is a high degree of convergence be- 
tween clinical activity and preclinical response in the stress 
model. 
Finally it should be noted that pharmacokinetic factors, 
which are critical at a clinical level, have not been investi- 
gated in the model. In this regard, it might be noted that a 
24--48 hr washout period preceded testing. Nonetheless, ac- 
tual serum drug levels are a more valid indicator, and ideally 
this factor should also be taken into account in any interpre- 
tation of drug efficacy. This points to an area of potential 
future investigation. 
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